WBL is rolling out a Rs 402-crore IPO comprising Rs 165 crore of recent instruct and an provide-for-sale in which one among the promoters is selling and the PE fund Tano India is offloading its entire 22% stake in WBL. From the IPO proceeds, Rs 50 crore is to be old for capex, Rs 48 crore for working capital and Rs 20 crore for debt compensation.
ET Intelligence Community: Unlike its name, Windlas Biotech (WBL) is no longer a biotech firm. The Dehradun-basically basically based entirely firm is a contract producer for over 200 formulation firms and is engaged in exchange generics and over-the-counter merchandise of nutraceuticals and health supplements.
WBL is rolling out a Rs 402-crore IPO comprising Rs 165 crore of recent instruct and an provide-for-sale in which one among the promoters is selling and the PE fund Tano India
BY
ET Bureau
3 minutes read, Final Updated:
AbcMinute
AbcMedium
AbcFat
₹399/month
Month-to-month
PLAN
Billed Quantity ₹399
No Trial Interval
₹208/month
(Attach 49%)
Yearly
PLAN
Billed Quantity ₹2,499
15
Days Trial
+Entails DocuBay and TimesPrime Membership.
₹150/month
(Attach 63%)
2-Year
PLAN
Billed Quantity ₹3,599
15
Days Trial
+Entails DocuBay and TimesPrime Membership.
Already a Member? Designate In now
Odd Financial Cases Stories, Editorials & Expert belief all the procedure through 20+ sectors
Stock analysis. Market Research. Industry Developments on 4000+ Stocks
Minimal Advertisements
